KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Current Assets (2016 - 2025)

Charles River Laboratories International (CRL) has 15 years of Current Assets data on record, last reported at $1.5 billion in Q1 2025.

  • For Q1 2025, Current Assets fell 9.7% year-over-year to $1.5 billion; the TTM value through Mar 2025 reached $1.5 billion, down 9.7%, while the annual FY2024 figure was $1.4 billion, 12.78% down from the prior year.
  • Current Assets reached $1.5 billion in Q1 2025 per CRL's latest filing, up from $1.4 billion in the prior quarter.
  • Across five years, Current Assets topped out at $1.7 billion in Q1 2024 and bottomed at $1.3 billion in Q4 2021.
  • Average Current Assets over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2023.
  • Peak YoY movement for Current Assets: grew 12.95% in 2022, then dropped 12.78% in 2024.
  • A 5-year view of Current Assets shows it stood at $1.3 billion in 2021, then rose by 12.95% to $1.4 billion in 2022, then increased by 11.79% to $1.6 billion in 2023, then dropped by 12.78% to $1.4 billion in 2024, then grew by 7.36% to $1.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $1.5 billion in Q1 2025, $1.4 billion in Q4 2024, and $1.5 billion in Q2 2024.